AKT1 and metastatic neoplasm: We demonstrated for the first time, that targeting sfRon downstream pathway at several fragile nodes (AKT, S6K1) by multi-kinase compound AD80 is the most effective strategy to achieve a sustained tumor growth inhibition and suppression of metastatic disease.